FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

WEDNESDAY, Jan. 22, 2025-- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants...